Mutant calreticulin in myeloproliferative neoplasms

Abstract excerpt

Recurrent mutations in calreticulin are present in ∼20% of patients with myeloproliferative neoplasms (MPNs). Since its discovery in 2013, we now have a more precise understanding of how mutant CALR, an endoplasmic reticulum chaperone protein, activates the JAK/STAT signaling pathway via a pathogenic binding interaction with the thrombopoietin receptor MPL to induce MPNs. In this Spotlight article, we review the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Myeloid Leukemia Treatments
• Share to Kruppel-like factors research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment